Personalized Tidal Volume in ARDS (VT4HEMOD)
Personalized Tidal Volume According to Cardiopulmonary Interactions in ARDS
Hospices Civils de Lyon
10 participants
Dec 29, 2022
INTERVENTIONAL
Conditions
Summary
Treatment of acute respiratory distress syndrome (ARDS) relies on invasive mechanical ventilation with supposedly protective settings (low tidal volume ventilation). Mortality of ARDS remains high in observational studies (40 to 50%). Approximately 30% of ARDS patients exhibit tidal hyperinflation despite low tidal volume ventilation, suggesting that personalization of tidal volume is required to improve ARDS prognostic. To date, reliable bedside tools to adjust tidal volume are lacking. Excessive tidal volume can be detected using computed tomography by quantification of tidal hyperinflation, but this technique is reserved to research studies and requires patient transport to imaging facility. Mechanical ventilation generates cardio-pulmonary interaction, whose magnitude is influenced by tidal volume and respiratory system characteristics. Pulse pressure variation is a bedside tool with potential to quantify cardio-pulmonary interactions. Increasing tidal volume will decrease right ventricular preload and increase right ventricular afterload, hence maximizing cardio-pulmonary interactions. The investigators hypothesize that pulse pressure variation might help to detect excessive tidal volume during a tidal volume challenge (i.e. stepwise increase in tidal volume)
Eligibility
Inclusion Criteria8
- Age greater then 18 years old
- ARDS according to the BERLIN definition with PaO2/FiO2 ratio ≤ 150 mm Hg
- invasive mechanical ventilation in volume controlled mode with tidal volume set to 6 ml/kg predicted body weight
- use of sedation and neuromuscular-blocking agents
- arterial catheter allowing computation of pulse contour cardiac output calibrated with thermodilution
- central venous catheter implanted in the superior vena cava territory
- esophageal balloon
- Computed tomography planned by attending physician
Exclusion Criteria25
- Previous inclusion in current study
- Acute cor pulmonale
- ECMO
- Arterial pH < 7.21 despite respiratory rate set to a maximum of 35/min
- Pneumothorax or bronchopleural fistula
- Decision to withdraw or withhold life sustaining treatment with 24 hours from inclusion
- Contra-indication of transport to imaging facility
- Intracranial hypertension
- Tricuspid or pulmonary mechanical valve
- Tricuspid or pulmonary infective endocarditis
- Pace maker with intracardiac leads
- Right ventricle tumor
- Complete left bundle block
- Intrathoracic metallic device
- COPD
- Cardiac arrythmia
- Vesical pressure > 15 mm Hg
- Lower limb amputation
- Inferior vena cava thrombosis
- Patient under an exclusion period relative to participation to another clinical trial
- Patient under a legal protective measure
- Patient not affiliated to social security
- lac of patient/representative consent
- Pregnancy
- Breast feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05406570